<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127681</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0390</org_study_id>
    <secondary_id>2019-A03281-56</secondary_id>
    <nct_id>NCT05127681</nct_id>
  </id_info>
  <brief_title>Bone Microarchitecture in Men With Hemophilia</brief_title>
  <acronym>HEMOS</acronym>
  <official_title>Bone Microarchitecture in Men With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilia A and B are hereditary sex-linked deficiencies of coagulation factors VIII and IX&#xD;
      characterized by bleeding. Their modern therapy increases life expectancy and risk of&#xD;
      age-related diseases, e.g., osteoporosis.&#xD;
&#xD;
      Hemophilia-specific risk factors impair formation of peak bone mass and accelerate bone loss.&#xD;
      Fractures are more frequent in hemophilic men vs. age-matched men and induce bleeding which&#xD;
      is aggravated by manipulations and surgical intervention.&#xD;
&#xD;
      The hypothesis of this study is that hemophilic men have poor bone microarchitecture&#xD;
      (assessed by High-resolution peripheral quantitative computed tomography (HR-pQCT)) related&#xD;
      to an imbalance between bone formation and resorption (assessed by bone turnover markers&#xD;
      (BTM) and bone biomarkers).&#xD;
&#xD;
      The study aims to assess the difference in low trabecular number (Tb.N) at the distal radius&#xD;
      between hemophilic men (cases) and age- height-weight-ethnicity and smoking-matched healthy&#xD;
      men (controls). Correlation between BTM and Tb.N will be also studied.&#xD;
&#xD;
      Biologic markers of bone remodeling (C-terminal telopeptide of type I collagen (PINP),&#xD;
      N-terminal propeptide of type I procollagen (CTX-I), periostin) will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of trabecular at distal tibia</measure>
    <time_frame>3 months following the inclusion</time_frame>
    <description>The number of trabecular at distal tibia will be performed and compared to the values available for the healthy control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of trabecular at distal radius</measure>
    <time_frame>3 months following the inclusion</time_frame>
    <description>The number of trabecular at distal radius will be performed and compared to the values available for the healthy control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sera bone remodeling biomarkers</measure>
    <time_frame>3 months following the inclusion</time_frame>
    <description>This biomarkers will be performed:&#xD;
PINP (ng/ml)&#xD;
CTX-1 (ng/ml)&#xD;
Periostin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reflection of bone strength</measure>
    <time_frame>3 months following the inclusion</time_frame>
    <description>Micro-Finite Element Analysis (µFEA) reflection of bone strength will be performed and compared to the values available for the healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Bone Score (TBS)</measure>
    <time_frame>3 months following the inclusion</time_frame>
    <description>Trabecular Bone Score (TBS) will be performed and compared to the values available for the healthy control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Severe Hemophilia A</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>severe hemophilia A or B patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy men</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the &quot;Institut national de la santé et de la recherche médicale&quot; (INSERM) research unit associated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HR-pQCT</intervention_name>
    <description>Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture</description>
    <arm_group_label>severe hemophilia A or B patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels</description>
    <arm_group_label>severe hemophilia A or B patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dual energy X-ray absorptiometry</intervention_name>
    <description>A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.</description>
    <arm_group_label>severe hemophilia A or B patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Any</intervention_name>
    <description>Data of healthy men is already available</description>
    <arm_group_label>healthy men</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Men aged 20 to 60 years&#xD;
&#xD;
          -  Severe hemophilia A or B (FVIII or FIX&lt;1%)&#xD;
&#xD;
          -  Regular followed up in Lyon Hemophilia Center&#xD;
&#xD;
          -  Ability to give free and informed consent&#xD;
&#xD;
          -  Person capable of actively participating in radiological examinations&#xD;
&#xD;
        Healthy Mens:&#xD;
&#xD;
          -  Aged 20 to 60 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  Not covered by health system&#xD;
&#xD;
          -  Vulnerable (adults unable to consent, protected under guardianship, prisoner)&#xD;
&#xD;
          -  Any blood coagulation abnormality other than severe hemophilia A or B&#xD;
&#xD;
          -  Having one of the following treatments against osteoporosis of more than 6 months :&#xD;
             bisphosphonates, denosumab, teriparatide&#xD;
&#xD;
          -  With a chronical disease having a high impact on bone structure and no related to&#xD;
             hemophilia disease, such as Cushing or Crohn diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dargaud Yesim, PU,PH</last_name>
    <phone>0472118810</phone>
    <phone_ext>+33</phone_ext>
    <email>gamze.dargaud@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Cardio-Vasculaire et Pneumologique</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DARGAUD Yesim, PU,PH</last_name>
      <phone>0472118810</phone>
      <phone_ext>+33</phone_ext>
      <email>gamze.dargaud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>DARGAUD Yesim, PU,PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>bone microarchitecture</keyword>
  <keyword>bone remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

